Cargando…

High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis

AIMS: To investigate the effect of high-dose iron vs. low-dose intravenous (IV) iron on myocardial infarction (MI) in patients on maintenance haemodialysis. METHODS AND RESULTS: This was a pre-specified analysis of secondary endpoints of the Proactive IV Iron Therapy in Hemodialysis Patients trial (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Petrie, Mark C, Jhund, Pardeep S, Connolly, Eugene, Mark, Patrick B, MacDonald, Michael R, Robertson, Michele, Anker, Stefan D, Bhandari, Sunil, Farrington, Kenneth, Kalra, Philip A, Wheeler, David C, Tomson, Charles R V, Ford, Ian, McMurray, John J V, Macdougall, Iain C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022850/ https://www.ncbi.nlm.nih.gov/pubmed/34875022 http://dx.doi.org/10.1093/cvr/cvab317

Ejemplares similares

Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes
por: Bhandari, Sunil, et al.
Publicado: (2023)

An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial
por: Thomson, Peter C., et al.
Publicado: (2022)

Association is not causation: treatment effects cannot be estimated from observational data in heart failure
por: Rush, Christopher J, et al.
Publicado: (2018)

Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial
por: Kassianides, Xenophon, et al.
Publicado: (2022)

The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
por: Rørth, Rasmus, et al.
Publicado: (2019)

Rationale and design of a randomised trial of intravenous iron in patients with heart failure
por: Kalra, Paul R, et al.
Publicado: (2022)

Efficacy of implantable haemodynamic monitoring in heart failure across ranges of ejection fraction: a systematic review and meta-analysis
por: Curtain, James P, et al.
Publicado: (2023)

Intravenous iron and erythropoiesis‐stimulating agents in haemodialysis: A systematic review and meta‐analysis
por: Roger, Simon D, et al.
Publicado: (2017)

The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan
por: Jhund, Pardeep S, et al.
Publicado: (2016)

A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients
por: Bhandari, Sunil, et al.
Publicado: (2015)

Treatment of Type 2 Diabetes and Outcomes in Patients With Heart Failure: A Nested Case–Control Study From the U.K. General Practice Research Database
por: MacDonald, Michael R., et al.
Publicado: (2010)

Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF
por: McEwan, Phil, et al.
Publicado: (2020)

Drug therapy for heart failure with reduced ejection fraction: what is the ‘right’ dose?
por: Kondo, Toru, et al.
Publicado: (2022)

Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction
por: Mooney, Leanne, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial
por: Roberts, Matthew A., et al.
Publicado: (2016)

A prospective study of fatigue trajectories among in‐centre haemodialysis patients
por: Picariello, Federica, et al.
Publicado: (2019)

A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status
por: Bhandari, S., et al.
Publicado: (2021)

Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER
por: Desai, Akshay S., et al.
Publicado: (2022)

Initiation of Medical Therapy for Heart Failure Patients According to Kidney Function: A Danish Nationwide Study
por: Zahir Anjum, Deewa, et al.
Publicado: (2023)

The Dapagliflozin and Prevention of Adverse outcomes in Heart Failure trial (DAPA-HF) in context
por: McMurray, John J V, et al.
Publicado: (2020)

Intravenous iron for heart failure with evidence of iron deficiency: a meta-analysis of randomised trials
por: Graham, Fraser J., et al.
Publicado: (2021)

Safety of intravenous iron use in chronic kidney disease
por: Kalra, Philip A., et al.
Publicado: (2016)

Heart failure and atrial flutter: a systematic review of current knowledge and practices
por: Diamant, Michael J., et al.
Publicado: (2021)

Estimating the Lifetime Benefits of Treatments for Heart Failure
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions
por: Macdougall, Iain C
Publicado: (2017)

What can we learn from RELAX-AHF compared to previous AHF trials and what does the future hold?
por: Cannon, Jane A, et al.
Publicado: (2015)

Cognitive-behavioural therapy (CBT) for renal fatigue (BReF): a feasibility randomised-controlled trial of CBT for the management of fatigue in haemodialysis (HD) patients
por: Picariello, Federica, et al.
Publicado: (2018)

Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox
por: Butt, Jawad H, et al.
Publicado: (2023)

Factors precipitating erythropoiesis‐stimulating agent responsiveness in a European haemodialysis cohort: case‐crossover study
por: Gillespie, Iain A., et al.
Publicado: (2015)

Rationale and methods of a randomized trial evaluating the effect of neprilysin inhibition on left ventricular remodelling
por: Docherty, Kieran F., et al.
Publicado: (2020)

Initiation of domiciliary care and nursing home admission following first hospitalization of heart failure patients: a nationwide cohort study
por: Rørth, Rasmus, et al.
Publicado: (2018)

Initiation of domiciliary care and nursing home admission following first hospitalization for heart failure, stroke, chronic obstructive pulmonary disease or cancer
por: Rørth, Rasmus, et al.
Publicado: (2021)

Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?
por: McDonagh, Theresa, et al.
Publicado: (2015)

Home haemodialysis: trends in technology
por: Farrington, Ken, et al.
Publicado: (2011)

The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial
por: Greenwood, Sharlene A, et al.
Publicado: (2020)

Change in renal function associated with drug treatment in heart failure: national guidance
por: Clark, Andrew L, et al.
Publicado: (2019)

Characteristics of Frailty in Haemodialysis Patients
por: Hendra, Heidy, et al.
Publicado: (2022)

Talking to patients with heart failure about end of life
por: Campbell, Ross T., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o4ilck0l1ubna3p528i0edgg2r